Drug Profile
KN 012
Alternative Names: KN 012Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Alphamab
- Developer Jiangsu Alphamab Biopharmaceuticals
- Class Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Osteoporosis in China (SC, Injection)
- 11 Feb 2022 KN 012 is still in preclinical trials for Osteoporosis in China (SC, Injection) (Alphamab pipeline, February 2022)
- 12 Jul 2019 KN 012 is still in preclinical trials for Osteoporosis in China (Alphamab pipeline, July 2019)